Analysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $33.00

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $33.00.

Several research analysts have recently commented on AVTX shares. Jefferies Financial Group assumed coverage on shares of Avalo Therapeutics in a research note on Tuesday. They set a “buy” rating and a $23.00 price target on the stock. BTIG Research initiated coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price target on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Piper Sandler started coverage on Avalo Therapeutics in a report on Friday, February 28th. They set an “overweight” rating and a $48.00 price objective on the stock. Finally, HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th.

Avalo Therapeutics Stock Performance

NASDAQ:AVTX opened at $8.73 on Tuesday. The stock’s 50 day moving average price is $7.59 and its 200 day moving average price is $9.13. Avalo Therapeutics has a 52 week low of $5.99 and a 52 week high of $34.46.

Institutional Trading of Avalo Therapeutics

Several hedge funds have recently added to or reduced their stakes in AVTX. Tower Research Capital LLC TRC increased its position in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after buying an additional 3,754 shares during the period. Marshall Wace LLP acquired a new stake in shares of Avalo Therapeutics in the fourth quarter worth $114,000. Walleye Capital LLC bought a new position in Avalo Therapeutics during the fourth quarter worth $145,000. Northern Trust Corp acquired a new position in Avalo Therapeutics during the 4th quarter valued at $168,000. Finally, Bank of Montreal Can bought a new stake in Avalo Therapeutics in the 4th quarter valued at $446,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.